Common Stock, $0.001 par value per share
- Symbol
- EBS
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Emergent Biosolutions, Inc.
EBSNYSEEQUITYCurrent
Other Events
Item 8.01 Other Events On November 4, 2026, Emergent BioSolutions Inc. (“Emergent”) announced that it has received a modification (the "Modification") exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War.…
Company context
Joseph Papa President and Chief Executive Officer Richard Lindahl EVP, Chief Financial Officer and Treasurer Jessica Perl SVP, General Counsel and Corporate Secretary Paul Williams SVP, Products Business Coleen Glessner EVP, Quality, Ethics and Compliance Simon Lowry, M.D. Chief Medical Officer, Head of Research and Development Stephanie Duatschek SVP, Chief Strategy and Transformation Officer Michelle Pepin SVP, Chief Human Resources Officer Bill Hartzel SVP, Manufacturing and Bioservices Emergent’s Executive Management Team
Current securities
Recent company filings
- 10-Q filingNov 3, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureNov 2, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 16, 2026
- Regulation FD DisclosureSep 14, 2026
- Other EventsSep 1, 2026
Registered securities in this filing
EMERGENT BIOSOLUTIONS INC. · 8-K · Filed 2026-11-04
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events
On November 4, 2026, Emergent BioSolutions Inc. (“Emergent”) announced that it has received a modification (the "Modification") exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War. The first delivery, which is valued at approximately $7.4 million, will begin this year, and remaining deliveries are expected in 2027.
The Modification is made under Emergent’s existing indefinite-delivery/indefinite-quantity contract, led by the Portfolio Management Executive for Chemical, Biological, Radiological and Nuclear Defense in collaboration with the Defense Health Agency to supply BioThrax® for use by all branches of the U.S. military as pre-exposure prophylaxis for anthrax disease. The preceding description of the Modification does not purport to be complete and is qualified in its entirety by reference to the full text of the Modification. The Modification will be filed as an exhibit to Emergent's Annual Report on Form 10-K for the fiscal year ended December 31, 2026.
On November 4, 2026, Emergent issued a press release announcing the Modification. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.